Abstract
Osteogenesis imperfecta (OI) is a genetic disease, characterized by changes in type I collagen, which determine a broad spectrum of clinical changes. Its occurrence in the population is from 1 to 10-20 thousand live births. Although there is no specific treatment, the medications of the class bisphosphonates are used with the aim of improving bone quality with reduction of fracture events…